Related Experiment Video

Updated: Aug 11, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease

A Bilici1, B Karadag, A Doventas

  • 1Department of Internal Medicine, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey. ahmetknower@softhome.net

The Netherlands Journal of Medicine
|February 3, 2005
PubMed

Insights

Retroperitoneal fibrosis (RPF) is a rare condition. This case study shows pergolide, a Parkinson's disease drug, may cause RPF, but symptoms improved after stopping the medication.

Area of Science:

  • Nephrology
  • Neurology
  • Pharmacology

Background:

  • Retroperitoneal fibrosis (RPF) is a rare condition potentially leading to ureteric obstruction and renal damage.
  • Pergolide, a dopamine agonist for Parkinson's disease, has been infrequently associated with RPF.
  • Idiopathic RPF is common, but drug-induced RPF requires careful consideration.

Purpose of the Study:

  • To report a rare case of drug-induced retroperitoneal fibrosis (RPF).
  • To highlight the potential association between pergolide use and RPF development.
  • To describe the management and outcome of RPF in a patient treated with pergolide.

Main Methods:

  • Case report of a 78-year-old woman with Parkinson's disease.
  • Clinical presentation of hydroureteronephrosis and subsequent RPF diagnosis.
  • Management included pergolide discontinuation and double-J stent placement.

Main Results:

  • The patient developed RPF and serosal fibrosis during pergolide treatment.
  • Renal function improved after pergolide withdrawal and stent placement.
  • Inflammatory markers normalized, and the fibrotic mass reduced within two months.

Conclusions:

  • Pergolide may be implicated in the development of retroperitoneal fibrosis.
  • Discontinuation of pergolide and supportive measures can lead to RPF improvement.
  • Early recognition and management are crucial for favorable outcomes in drug-induced RPF.

More Related Videos

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage04:25

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage

Published on: April 28, 2022

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease02:21

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease

Published on: March 15, 2024

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...